A Phase II, Randomized, Modified Single-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma.

Trial Profile

A Phase II, Randomized, Modified Single-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2011

At a glance

  • Drugs Bedoradrine (Primary)
  • Indications Acute asthma; Status asthmaticus
  • Focus Therapeutic Use
  • Sponsors MediciNova
  • Most Recent Events

    • 04 Nov 2010 Results were presented at the 76th Annual Meeting of the American College of Chest Physicians.
    • 28 Oct 2010 Data were presented at the 2010 Annual Meeting of the American College of Chest Physicians, according to a MediciNova media release.
    • 28 May 2009 Status changed from recruiting to completed. This trial has recently been completed according to a MediciNova media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top